A popular FDA program that aims to assess the manufacturing maturity of medical device firms is undergoing a name change.
The Voluntary Medical Device Manufacturing and Product Quality Pilot Program – a title that never easily rolled off the...
What's In A Name? FDA To Rechristen Its Popular CMMI Maturity Model Appraisal Program This Year
Listen to this article
The joint US FDA/MDIC Voluntary Medical Device Manufacturing and Product Quality Pilot Program – which aims to assess the manufacturing maturity of device firms – will be renamed the "Case for Quality Voluntary Improvement Program," or CFQ VIP. Meanwhile, MDIC says it has launched a new working group to guide development of the burgeoning initiative.
Keep up with the top medtech business and regulatory news.
More from Regulation
In this week’s Digital Health Roundup, Medtech Insight’s Ryan Nelson highlights Click Therapeutics’ FDA-cleared digital therapeutics (DTx) for depression and Sinaptica Therapeutics’ personalized neuromodulation for Alzheimer’s patients. Marion Webb discusses her interview with MindMaze’s John Krakauer on their gaming-focused DTx to help people recover from serious brain injuries. Elizabeth Orr introduces new voting members of the new Digital Health Advisory Committee and Natasha Barrow discusses Hello Heart’s new symptom-tracking feature in their heart-focused app.
This week, Establishment Labs Holdings announced the FDA gave it premarket approval for Motiva breast implant, Cologuard lands FDA approval for Cologuard Plus and GE HealthCare gets FDA nod for a new imaging agent. The FDA announces another expansion for TAP into ophthalmology and radiology. The AAMI and CTA will join forces to develop standards for AI and ML-enabled health care products.
- • By
Children with biliary atresia (BA) exhibited neurodevelopmental deficits and increased autism traits, with earlier surgery linked to better general neurodevelopment.
- • By
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.
More from Policy & Regulation
This week, Establishment Labs Holdings announced the FDA gave it premarket approval for Motiva breast implant, Cologuard lands FDA approval for Cologuard Plus and GE HealthCare gets FDA nod for a new imaging agent. The FDA announces another expansion for TAP into ophthalmology and radiology. The AAMI and CTA will join forces to develop standards for AI and ML-enabled health care products.
- • By
Children with biliary atresia (BA) exhibited neurodevelopmental deficits and increased autism traits, with earlier surgery linked to better general neurodevelopment.
